Peripheral neuropathies and anti-glycolipid antibodies
The DOI matches its Crossref record; 296 of the 296 references it cites were found in a registry or an index.
Abstract
This review charts the progress of anti-glycolipid antibodies in neuropathy, from their original discovery 20 years ago in immunoglobulin M paraproteinaemic neuropathy through to current discoveries mapping their relationship to subtypes of Guillain-Barré syndrome. Antibodies to >20 different glycolipids have now been associated with a wide range of clinically identifiable acute and chronic neuropathy syndromes. Particular progress has been achieved in understanding the link between acute motor axonal neuropathy and antibodies to GM1, GD1a, GM1b and GalNAc-GD1a, and between the cranial, bulbar and sensory variants of GBS and antibodies to the disialylated gangliosides GQ1b, GT1a, GD1b and GD3. In addition to clinical and serological studies, the origins and measurement of anti-glycolipid antibodies and their relationships to similar carbohydrate structures on infectious organisms, particularly Campylobacter jejuni, are discussed in the context of a molecular mimicry hypothesis. The structure and nomenclature of relevant glycolipids are outlined, along with information on their localization in nerve, and the influence this has on clinical phenotypes. Major advances have been made in animal modelling of anti-glycolipid antibody-associated diseases, both in vitro and in vivo. This has advanced our understanding of the role of anti-GQ1b antibodies in Miller Fisher syndrome with particular respect to the motor nerve terminal as a potential site of injury, and led to the creation of rabbit models of anti-GD1b and anti-GM1 antibody-mediated sensory and motor neuropathy, respectively. With such information in place, it will now be possible to determine the precise mechanisms by which antibodies injure the different compartments of peripheral nerve and establish how a range of immunomodulating therapies, including current treatments, exert their therapeutic effects. Despite these very significant advances, considerable gaps in our knowledge persist, and it is likely that other pathogenic pathways operate in inflammatory neuropathy that are unrelated to glycolipid antibodies, although these are outside the scope of this review.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the latter instance rare human immune responses against the ganglioside-like structures can even result in serious illness, with the complementfi xing antibodies damaging peripheral nerves (Guillain-Barré syndrome) (990 -991).”
From Biological roles of glycans (2017) · cites this paper as [990]
Citations
Cites
Functional rafts in cell membranes
Simons, K., & Ikonen, E. (1997) · Nature · doi:10.1038/42408 · Cited by 9,757
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
Fisher, M. (1956) · New England Journal of Medicine · doi:10.1056/nejm195607122550201 · Cited by 1,069
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome
Hadden, R. D. M., Cornblath, D. R., Hughes, R. A. C., Zielasek, J., Hartung, H. ‐., Toyka, K. V., Swan, A. V., & The Plasma Exchange/Sandoglobulin Guillain‐Barré Syndrome Trial Group (1998) · Annals of Neurology · doi:10.1002/ana.410440512 · Cited by 942
The spectrum of antecedent infections in Guillain-Barré syndrome: A case-control study
Jacobs, B. C., Rothbarth, P. H., van der Meché, F. G. A., Herbrink, P., Schmitz, P. I. M., de Klerk, M. A., & van Doorn, P. A. (1998) · Neurology · doi:10.1212/wnl.51.4.1110 · Cited by 826
Defining criteria for autoimmune diseases (Witebsky's postulates revisited)
Rose, N. R., & Bona, C. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90244-f · Cited by 814
Campylobacter jejuni Infection and Guillain–Barré Syndrome
Rees, J. H., Soudain, S. E., Gregson, N. A., & Hughes, R. A. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332102 · Cited by 753
THE INFLAMMATORY LESION IN IDIOPATHIC POLYNEURITIS
ASBURY, A. K., ARNASON, B. G., & ADAMS, R. D. (1969) · Medicine · doi:10.1097/00005792-196905000-00001 · Cited by 723
Chiba, A., Kusunoki, S., Obata, H., Machinami, R., & Kanazawa, I. (1993) · Neurology · doi:10.1212/wnl.43.10.1911 · Cited by 705
[10] Gangliosides: Structure, isolation, and analysis
Ledeen, R. W., & Yu, R. K. (1982) · Methods in Enzymology · doi:10.1016/0076-6879(82)83012-7 · Cited by 701
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“In the latter instance rare human immune responses against the ganglioside-like structures can even result in serious illness, with the complement-fixing antibodies damaging peripheral nerves (Guillain-Barré syndrome) (990, 991).”
BackgroundHughes, R. A., & Cornblath, D. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67665-9 · Cited by 1,676
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Self-citationGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B. C., & van Doorn, P. A. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.121 · Cited by 1,101
Irani, S. R., Bera, K., Waters, P., Zuliani, L., Maxwell, S., Zandi, M. S., Friese, M. A., Galea, I., Kullmann, D. M., Beeson, D., et al. (2010) · Brain · doi:10.1093/brain/awq113 · Cited by 1,035
“, 2009) as clearly demonstrated, for instance, in patients with Guillain–Barré syndrome (Willison and Yuki, 2002).”
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
van Doorn, P. A., Ruts, L., & Jacobs, B. C. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70215-1 · Cited by 828
Joint Task Force of the EFNS and the PNS (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00290.x · Cited by 568
Atkinson, T. P., Balish, M. F., & Waites, K. B. (2008) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2008.00129.x · Cited by 497
Immunotherapy for Guillain-Barre syndrome: a systematic review
Hughes, R. A. C., Swan, A. V., Raphael, J.-C., Annane, D., van Koningsveld, R., & van Doorn, P. A. (2007) · Brain · doi:10.1093/brain/awm004 · Cited by 463
The role of infections in autoimmune disease
Ercolini, A. M., & Miller, S. D. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2008.03834.x · Cited by 413
Zika virus-associated neurological disorders: a review
Araujo, A. Q. C., Silva, M. T. T., & Araujo, A. P. Q. C. (2016) · Brain · doi:10.1093/brain/aww158 · Cited by 406
Adverse Effects of Vaccines: Evidence and Causality
Stratton, K. R., Ford, A. Q., Rusch, E., & Clayton, E. W. (2013) · Cited by 348
Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome
Keddie, S., Pakpoor, J., Mousele, C., Pipis, M., Machado, P. M., Foster, M., Record, C. J., Keh, R. Y. S., Fehmi, J., Paterson, R. W., et al. (2021) · Brain · doi:10.1093/brain/awaa433 · Cited by 333
Self-citationMyelin‐associated glycoprotein (MAG): past, present and beyond
Quarles, R. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04319.x · Cited by 326
The Guillain–Barré syndrome: a true case of molecular mimicry
Wim Ang, C., Jacobs, B. C., & Laman, J. D. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.12.004 · Cited by 326
Gangliosides in cell recognition and membrane protein regulation
Lopez, P. H., & Schnaar, R. L. (2009) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.06.001 · Cited by 311
Agmon-Levin, N., Paz, Z., Israeli, E., & Shoenfeld, Y. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.196 · Cited by 249
Neurofascin as a target for autoantibodies in peripheral neuropathies
Ng, J. K. M., Malotka, J., Kawakami, N., Derfuss, T., Khademi, M., Olsson, T., Linington, C., Odaka, M., Tackenberg, B., Prüss, H., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31827689ad · Cited by 248
Uncini, A., Susuki, K., & Yuki, N. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.03.025 · Cited by 248
Fiore, A. E., Bridges, C. B., & Cox, N. J. (2009) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-92165-3_3 · Cited by 243
Antibodies Against Laminaribioside and Chitobioside Are Novel Serologic Markers in Crohn’s Disease
Dotan, I., Fishman, S., Dgani, Y., Schwartz, M., Karban, A., Lerner, A., Weishauss, O., Spector, L., Shtevi, A., Altstock, R. T., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.030 · Cited by 234
Antecedent infections in Fisher syndrome: A common pathogenesis of molecular mimicry
Koga, M., Gilbert, M., Li, J., Koike, S., Takahashi, M., Furukawa, K., Hirata, K., & Yuki, N. (2005) · Neurology · doi:10.1212/01.wnl.0000160399.08456.7c · Cited by 233
Godschalk, P. C. R., Heikema, A. P., Gilbert, M., Komagamine, T., Ang, C. W., Glerum, J., Brochu, D., Li, J., Yuki, N., Jacobs, B. C., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci15707 · Cited by 231
Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications
Querol, L., Devaux, J., Rojas-Garcia, R., & Illa, I. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.84 · Cited by 227
Kieseier, B. C., Kiefer, R., Gold, R., Hemmer, B., Willison, H. J., & Hartung, H. (2004) · Muscle & Nerve · doi:10.1002/mus.20076 · Cited by 210
Self-citationMultifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies
Vlam, L., van der Pol, W.-L., Cats, E. A., Straver, D. C., Piepers, S., Franssen, H., & van den Berg, L. H. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.175 · Cited by 209
Functional Roles of Gangliosides in Neurodevelopment: An Overview of Recent Advances
Yu, R. K., Tsai, Y.-T., & Ariga, T. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0744-y · Cited by 203
Nodal proteins are target antigens in Guillain‐Barré syndrome
Devaux, J. J., Odaka, M., & Yuki, N. (2012) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2012.00372.x · Cited by 193
Multifocal motor neuropathy: Current concepts and controversies
Nobile‐Orazio, E., Cappellari, A. M., & Priori, A. (2005) · Muscle & Nerve · doi:10.1002/mus.20296 · Cited by 190
The immunobiology of Guillain‐Barré syndromes
Willison, H. J. (2005) · Journal of the Peripheral Nervous System · doi:10.1111/j.1085-9489.2005.0010202.x · Cited by 189
Self-citationA controlled investigation of the cause of chronic idiopathic axonal polyneuropathy
Hughes, R. A. C. (2004) · Brain · doi:10.1093/brain/awh192 · Cited by 178
Intravenous immunoglobulin for multifocal motor neuropathy
van Schaik, I. N., van den Berg, L. H., de Haan, R., & Vermeulen, M. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004429.pub2 · Cited by 174
Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies)
Kuntzer, T., Antoine, J., & Steck, A. J. (2004) · Muscle & Nerve · doi:10.1002/mus.20100 · Cited by 173
van Schaik, I. N., Bouché, P., Illa, I., Léger, J. M., den Bergh, P. Y. K. V., Cornblath, D. R., Evers, E., Hadden, R. D. M., Hughes, R. A., Koski, C. L., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01466.x · Cited by 172
Kieseier, B. C., Mathey, E. K., Sommer, C., & Hartung, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0027-2 · Cited by 172
Ganglioside complexes as new target antigens in Guillain–Barré syndrome
Kaida, K., Morita, D., Kanzaki, M., Kamakura, K., Motoyoshi, K., Hirakawa, M., & Kusunoki, S. (2004) · Annals of Neurology · doi:10.1002/ana.20222 · Cited by 170
Neurotoxicity assessment using zebrafish
Parng, C., Roy, N. M., Ton, C., Lin, Y., & McGrath, P. (2007) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2006.04.004 · Cited by 169
Yu, R. K., Usuki, S., & Ariga, T. (2006) · Infection and Immunity · doi:10.1128/iai.00967-06 · Cited by 142
Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy
Hughes, R. A., Allen, D. C., Makowska, A. M., & Gregson, N. A. (2006) · Journal of the Peripheral Nervous System · doi:10.1111/j.1085-9489.2006.00061.x · Cited by 160
Kaida, K., Ariga, T., & Yu, R. K. (2009) · Glycobiology · doi:10.1093/glycob/cwp027 · Cited by 155
Halstead, S. K., O'Hanlon, G. M., Humphreys, P. D., Morrison, D. B., Morgan, B. P., Todd, A. J., Plomp, J. J., & Willison, H. J. (2004) · Brain · doi:10.1093/brain/awh231 · Cited by 152
Self-citationPathogenesis of immune-mediated neuropathies
Dalakas, M. C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.013 · Cited by 147
Inactivated influenza vaccines
Fiore, A. E., Bridges, C. B., Katz, J. M., & Cox, N. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00026-4 · Cited by 147
Acute motor conduction block neuropathy Another Guillain–Barré syndrome variant
Capasso, M., Caporale, C. M., Pomilio, F., Gandolfi, P., Lugaresi, A., & Uncini, A. (2003) · Neurology · doi:10.1212/wnl.61.5.617 · Cited by 146
Multifocal motor neuropathy: Association of anti-GM1 IgM antibodies with clinical features
Cats, E. A., Jacobs, B. C., Yuki, N., Tio‐Gillen, A. P., Piepers, S., Franssen, H., van Asseldonk, J. T., van den Berg, L. H., & van der Pol, W. L. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ff94c2 · Cited by 142
Differentiating lower motor neuron syndromes
Garg, N., Park, S. B., Vucic, S., Yiannikas, C., Spies, J., Howells, J., Huynh, W., Matamala, J. M., Krishnan, A. V., Pollard, J. D., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313526 · Cited by 141
Koga, M., Gilbert, M., Takahashi, M., Li, J., Koike, S., Hirata, K., & Yuki, N. (2006) · The Journal of Infectious Diseases · doi:10.1086/499969 · Cited by 126
Goodfellow, J. A., Bowes, T., Sheikh, K. A., Odaka, M., Halstead, S. K., Humphreys, P. D., Wagner, E. R., Yuki, N., Furukawa, K., Furukawa, K., et al. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4279-04.2005 · Cited by 134
Self-citationAvril, T., Wagner, E. R., Willison, H. J., & Crocker, P. R. (2006) · Infection and Immunity · doi:10.1128/iai.02094-05 · Cited by 133
Self-citationMultifocal motor neuropathy with and without conduction block: A single entity?
Delmont, É., Azulay, J., Giorgi, R., Attarian, S., Verschueren, A., Uzenot, D., & Pouget, J. (2006) · Neurology · doi:10.1212/01.wnl.0000234063.51897.20 · Cited by 132
Campylobacter gene polymorphism as a determinant of clinical features of Guillain–Barré syndrome
Koga, M., Takahashi, M., Masuda, M., Hirata, K., & Yuki, N. (2005) · Neurology · doi:10.1212/01.wnl.0000176914.70893.14 · Cited by 112
Greenshields, K. N., Halstead, S. K., Zitman, F. M. P., Rinaldi, S., Brennan, K. M., O’Leary, C., Chamberlain, L. H., Easton, A., Roxburgh, J., Pediani, J. D., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37338 · Cited by 127
Self-citationInfectious causes of acute flaccid paralysis
Solomon, T., & Willison, H. J. (2003) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200310000-00002 · Cited by 127
Self-citationMultifocal motor neuropathy: controversies and priorities
Yeh, W. Z., Dyck, P. J. B., van den Berg, L. H., Kiernan, M. C., & Taylor, B. V. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321532 · Cited by 125
Microbial Translocation Correlates with the Severity of Both HIV‐1 and HIV‐2 Infections
Nowroozalizadeh, S., Månsson, F., da Silva, Z. J., Repits, J., Dabo, B., Pereira, C. C., Biague, A. J., Albert, J., Nielsen, J. O., Aaby, P., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/651430 · Cited by 125
Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination
Clark, A. J., Kaller, M. S., Galino, J., Willison, H. J., Rinaldi, S., & Bennett, D. (2017) · Brain · doi:10.1093/brain/awx012 · Cited by 124
Self-citationAnti-ganglioside complex antibodies associated with severe disability in GBS
Kaida, K.-I., Morita, D., Kanzaki, M., Kamakura, K., Motoyoshi, K., Hirakawa, M., & Kusunoki, S. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.09.013 · Cited by 122
Pathophysiology of human paralytic rabies
Hemachudha, T., Wacharapluesadee, S., Mitrabhakdi, E., sup, H. W. S., sup, K. M. S., & sup, A. R. L. S. (2005) · Journal of NeuroVirology · doi:10.1080/13550280590900409 · Cited by 121
Korinthenberg, R., Trollmann, R., Felderhoff‐Müser, U., Bernert, G., Hackenberg, A., Hufnagel, M., Pohl, M., Hahn, G., Mentzel, H., Sommer, C., et al. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2020.01.003 · Cited by 120
Guillain-Barré syndrome: expanding the concept of molecular mimicry
Laman, J. D., Huizinga, R., Boons, G., & Jacobs, B. C. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.02.003 · Cited by 121
Designer probiotics for prevention of enteric infections
Paton, A. W., Morona, R., & Paton, J. C. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1349 · Cited by 120
Aixinjueluo, W., Furukawa, K., Zhang, Q., Hamamura, K., Tokuda, N., Yoshida, S., Ueda, R., & Furukawa, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414041200 · Cited by 119
Chiu, C., Lairson, L. L., Gilbert, M., Wakarchuk, W. W., Withers, S. G., & Strynadka, N. C. J. (2007) · Biochemistry · doi:10.1021/bi602543d · Cited by 118
zu Hörste, G. M., Hartung, H., & Kieseier, B. C. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0452 · Cited by 113
Recombinant Probiotics for Treatment and Prevention of Enterotoxigenic Escherichia coli Diarrhea
Paton, A. W., Jennings, M. P., Morona, R., Wang, H., Focareta, A., Roddam, L. F., & Paton, J. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.050 · Cited by 113
Beadon, K., Guimarães‐Costa, R., & Léger, J. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000605 · Cited by 113
A Recombinant Probiotic for Treatment and Prevention of Cholera
Focareta, A., Paton, J. C., Morona, R., Cook, J., & Paton, A. W. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.005 · Cited by 110
Guillain-Barré syndrome and anti-ganglioside antibodies: A clinician-scientist’s journey
YUKI, N. (2012) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.88.299 · Cited by 109
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders
Rinaldi, S., Davies, A. J., Fehmi, J., Beadnall, H. N., Wang, J., Hardy, T. A., Barnett, M. H., Broadley, S., Waters, P. J., Reddel, S., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000924 · Cited by 106
Martini, R., & Willison, H. (2016) · Glia · doi:10.1002/glia.22899 · Cited by 92
Self-citationAnti-Glycan Antibodies as Biomarkers for Diagnosis and Prognosis
Dotan, N., Altstock, R. T., Schwarz, M., & Dukler, A. (2006) · Lupus · doi:10.1191/0961203306lu2331oa · Cited by 104
Heikema, A. P., Bergman, M. P., Richards, H., Crocker, P. R., Gilbert, M., Samsom, J. N., van Wamel, W. J. B., Endtz, H. P., & van Belkum, A. (2010) · Infection and Immunity · doi:10.1128/iai.01273-09 · Cited by 103
The role of phage display in therapeutic antibody discovery
Chan, C. E. Z., Lim, A. P. C., MacAry, P. A., & Hanson, B. J. (2014) · International Immunology · doi:10.1093/intimm/dxu082 · Cited by 103
Querol, L., Siles, A. M., Alba-Rovira, R., Jáuregui, A., Devaux, J. J., Faivre‐Sarrailh, C., Araque, J., Rojas‐García, R., Díaz‐Manera, J., Cortés‐Vicente, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14853-4 · Cited by 103
Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA
Kuijf, M. L., van Doorn, P. A., Tio‐Gillen, A. P., Geleijns, K. P. W., Ang, C. W., Hooijkaas, H., Hop, W. C. J., & Jacobs, B. C. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.07.009 · Cited by 103
Kaida, K., & Kusunoki, S. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.02.001 · Cited by 100
The role of cytokines in Guillain–Barré syndrome
Lu, M., & Zhu, J. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5836-5 · Cited by 99
Lehmann, H. C., Lopez, P. H. H., Zhang, G., Ngyuen, T., Zhang, J., Kieseier, B. C., Mori, S., & Sheikh, K. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4017-06.2007 · Cited by 90
O’Hanlon, G. M., Humphreys, P. D., Goldman, R. S., Halstead, S. K., Bullens, R. W. M., Plomp, J. J., Ushkaryov, Y. A., & Willison, H. J. (2003) · Brain · doi:10.1093/brain/awg254 · Cited by 98
Self-citationGuillain Barre Syndrome as a Complication of COVID-19: A Systematic Review
Aladawi, M., Elfil, M., Abu-Esheh, B., Jazar, D. A., Armouti, A. O., Bayoumi, A., & Piccione, E. A. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.102 · Cited by 97
Plomp, J. J., & Willison, H. J. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.171702 · Cited by 97
Self-citationGlycosylation of Glycolipids in Cancer: Basis for Development of Novel Therapeutic Approaches
Daniotti, J. L., Vilcaes, A. A., Demichelis, V. T., Ruggiero, F. M., & Rodríguez‐Walker, M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00306 · Cited by 96
Immune-Mediated Neuropathies: Pathophysiology and Management
Shastri, A., Aiyan, A. A., Kishore, U., & Farrugia, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087288 · Cited by 96
Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial
Piepers, S., van den Berg‐Vos, R. M., der Pol, W.-L. V., Franssen, H., Wokke, J. H. J., & van den Berg, L. H. (2007) · Brain · doi:10.1093/brain/awm144 · Cited by 95
ADAM17 at the interface between inflammation and autoimmunity
Lisi, S., D’Amore, M., & Sisto, M. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.08.008 · Cited by 95
Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
Albarrán, V., Chamorro, J., Rosero, D. I., Saavedra, C., Soria, A., Carrato, A., & Gajate, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.774170 · Cited by 93
Antibodies against ganglioside complexes in Guillain‐Barré syndrome and related disorders
Kusunoki, S., & Kaida, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07029.x · Cited by 83
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Lehmann, H. C., Hartung, H.-P., Hetzel, G. R., Stüve, O., & Kieseier, B. C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.8.1066 · Cited by 92
Kim, J. K., Bae, J. S., Kim, D., Kusunoki, S., Kim, J., Kim, J. S., Park, Y. E., Park, K., Song, H. S., Kim, S., et al. (2014) · Journal of Clinical Neurology · doi:10.3988/jcn.2014.10.2.94 · Cited by 92
Susceptibility to Guillain–Barré syndrome is associated to polymorphisms of CD1 genes
Caporale, C. M., Papola, F., Fioroni, M. A., Aureli, A., Giovannini, A., Notturno, F., Adorno, D., Caporale, V., & Uncini, A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.05.018 · Cited by 91
Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies
Sommer, C., Brandner, S., Dyck, P. J. B., Harati, Y., Lacroix, C., Lammens, M. M. Y., Magy, L., Mellgren, S. I., Morbin, M., Navarro, C., et al. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00276.x · Cited by 89
Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?
Brettschneider, J., Petzold, A., Süßmuth, S. D., & Tumani, H. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0097-x · Cited by 88
Zhang, G., Lopez, P. H. H., Li, C. Y., Mehta, N. R., Griffin, J. W., Schnaar, R. L., & Sheikh, K. A. (2004) · Brain · doi:10.1093/brain/awh127 · Cited by 88
Nodes, paranodes and neuropathies
Fehmi, J., Scherer, S. S., Willison, H. J., & Rinaldi, S. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-315480 · Cited by 88
Self-citationGlycolipid antigens and autoantibodies in autoimmune neuropathies
Willison, H. J., & Goodyear, C. S. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.05.001 · Cited by 86
Self-citationA controlled trial of intravenous immunoglobulin in multifocal motor neuropathy
Hahn, A. F., Beydoun, S. R., Lawson, V. H., for The IVIG in MMN Study Team, Oh, M., Empson, V. G., Leibl, H., Ngo, L. Y., Gelmont, D. M., & Koski, C. L. (2013) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12046 · Cited by 86
McGonigal, R., Cunningham, M. E., Yao, D., Barrie, J. A., Sankaranarayanan, S., Fewou, S. N., Furukawa, K., Yednock, T. A., & Willison, H. J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0291-x · Cited by 77
Self-citationModulation of Glycan Recognition by Clustered Saccharide Patches
(2014) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-800097-7.00003-8 · Cited by 84
The Neuroimmunology of Guillain-Barré Syndrome and the Potential Role of an Aging Immune System
Hagen, K. M., & Ousman, S. S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.613628 · Cited by 85
Antibody Responses to Mycoplasma pneumoniae: Role in Pathogenesis and Diagnosis of Encephalitis?
Sauteur, P. M. M., Jacobs, B. C., Spuesens, E. B. M., Jacobs, E., Nadal, D., Vink, C., & van Rossum, A. M. C. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003983 · Cited by 83
Metadata
- Authors
- Willison, H. J.
- Affiliations
- Southern General Hospital (GB)
- Corresponding author
- Willison, H. J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-12-01
- Volume
- 125
- Issue
- 12
- Pages
- 2591-2625
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2021949020
- Cited by
- 710
- References
- 286
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 19 · 2023: 22 · 2022: 16 · 2021: 21 · 2020: 19 · 2019: 12 · 2018: 20 · 2017: 23 · 2016: 34 · 2015: 30 · 2014: 37 · 2013: 32 · 2012: 33
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- anti-glycolipid antibodies, peripheral neuropathy, Guillain-Barré syndrome, Miller Fisher syndrome, acute motor axonal neuropathy, gangliosides, GM1, GD1a, GQ1b, Campylobacter jejuni, molecular mimicry, sensory neuropathy, immunomodulatory therapy
- MeSH terms
- Animals, Autoantibodies, Glycolipids, Humans, Immunoglobulin G, Immunoglobulin M, Peripheral Nervous System Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.